Today’s Stock On Watch: Puma Biotechnology Inc’s Stock Is Sell After Today’s Significant Decline

Today's Stock On Watch: Puma Biotechnology Inc's Stock Is Sell After Today's Significant Decline

The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! The stock decreased 4.28% or $2.87 during the last trading session, hitting $64.18. About 773,256 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 38.62% since March 1, 2016 and is uptrending. It has outperformed by 26.40% the S&P500.
The move comes after 8 months negative chart setup for the $2.12B company. It was reported on Oct, 4 by Barchart.com. We have $59.05 PT which if reached, will make NYSE:PBYI worth $169.60 million less.

Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 earnings per share, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual earnings per share reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage

Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 29. The stock of Puma Biotechnology Inc (NYSE:PBYI) has “Buy” rating given on Monday, April 11 by UBS. Citigroup initiated the stock with “Neutral” rating in Thursday, September 3 report. On Thursday, August 27 the stock rating was initiated by JP Morgan with “Overweight”. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Outperform” rating by Credit Suisse on Thursday, January 21. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Buy” rating by Citigroup on Monday, December 14. RBC Capital Markets downgraded Puma Biotechnology Inc (NYSE:PBYI) on Tuesday, March 29 to “Sector Perform” rating. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, September 21. The firm has “Buy” rating by Citigroup given on Tuesday, March 29. Credit Suisse maintained the stock with “Outperform” rating in Thursday, September 22 report.

According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”

Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.18, from 1.03 in 2016Q1. The ratio is positive, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Jpmorgan Chase & Com has invested 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). The Connecticut-based Aqr Capital Mgmt Limited Co has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). Cubist Systematic Strategies Ltd has 0.01% invested in the company for 3,610 shares. The United Kingdom-based Blackrock Gp Ltd has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). The California-based Schwab Charles Inc has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). Ladenburg Thalmann Financial Services has 0% invested in the company for 74 shares. Diam Limited last reported 0.08% of its portfolio in the stock. Eaton Vance, a Massachusetts-based fund reported 142,000 shares. Blackrock Japan last reported 37 shares in the company. The New York-based Global X Co Limited Liability Com has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). The Pennsylvania-based Cordasco Fincl Network has invested 0.03% in Puma Biotechnology Inc (NYSE:PBYI). Partner Fund Management Limited Partnership, a California-based fund reported 1.47 million shares. Moreover, Bb Biotech Ag has 0.51% invested in Puma Biotechnology Inc (NYSE:PBYI) for 431,991 shares. Rock Springs Management Lp last reported 0.07% of its portfolio in the stock. D E Shaw Communications Inc holds 0.01% or 135,727 shares in its portfolio.

More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Equitiesfocus.com which released: “Puma Biotechnology Inc (NYSE:PBYI) Reported Basic Consolidated EPS Of $-7.4483” on April 20, 2016, also Fool.com with their article: “Why Puma Biotechnology Inc Roared Higher Today” published on September 20, 2016, Fool.com published: “Why Puma Biotechnology, Inc. Stock Crashed 37% in March” on April 11, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Fool.com and their article: “Why Puma Biotechnology, Inc. Stock Soared 65.1% in July” published on August 04, 2016 as well as Schaeffersresearch.com‘s news article titled: “Puma Biotechnology Inc (PBYI) Calls Active Despite Scandal” with publication date: September 30, 2016.

PBYI Company Profile

Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment